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1. INTRODUCTION {#jcmm13881-sec-0001}
===============

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of death from cancer,[1](#jcmm13881-bib-0001){ref-type="ref"} causing an estimated 8% of all cancer deaths. Lynch syndrome (LS) or hereditary nonpolyposis CRC is an autosomal dominant syndrome that accounts for about 1%‐3% of all CRC cases.[2](#jcmm13881-bib-0002){ref-type="ref"}, [3](#jcmm13881-bib-0003){ref-type="ref"} LS is the most common inherited cause of CRC and is caused by pathogenic germline mutations in one of four DNA mismatch repair (MMR) genes (*MLH1*,*MSH2*,*MSH6*, and *PMS2*).[4](#jcmm13881-bib-0004){ref-type="ref"} Carriers of LS mutations have an estimated 25%‐75% life‐time risk of CRC as well as increased risk of several other cancer types, including endometrial and ovarian cancer.[5](#jcmm13881-bib-0005){ref-type="ref"} Due to the low frequency of LS and heterogeneity in phenotypic expression, it has proven difficult to accurately establish population prevalence and to assess the penetrance of LS mutations.[6](#jcmm13881-bib-0006){ref-type="ref"}

About 15% of CRC cases are somatically hypermutated as a consequence of MMR deficiency. Of these, 1%‐3% are due to LS while most of the remaining MMR‐deficient tumours have somatic inactivation of *MLH1* via hypermethylation of the gene promoter.[7](#jcmm13881-bib-0007){ref-type="ref"} In MMR‐deficient tumours, both copies of the same MMR gene have been inactivated, resulting in no production of the respective protein product. MMR‐deficient tumours exhibit several clinical characteristics that have implication for therapy, in particular with regard to the use of immune system modulators.[8](#jcmm13881-bib-0008){ref-type="ref"} Therefore, universal screening of CRC tumours, using microsatellite testing or immunohistochemistry (IHC) for the MMR proteins, has been recommended by several groups in Europe and the United States.[9](#jcmm13881-bib-0009){ref-type="ref"}

To date, nothing is known about the prevalence of LS in the Romanian population and no mutations have been reported. The ROMCAN Project ("Genetic Epidemiology of Cancer in Romania") started in 2012 with the major aim of characterizing genetic risk factors for CRC, breast cancer (BRC), prostate cancer (PrCa), and lung cancer (LuCa) in the Romanian population. The second goal of the ROMCAN Project is to define high‐risk groups for whom specific preventive measures can be implemented.

The objective of this study is to start assessing the impact of LS variants in CRC in Romania and provide a framework for screening in high‐risk families. Our present study was designed to identify high‐risk mutations in six CRC genes using whole‐genome sequencing (WGS). The frequencies of all candidate variants were then assessed in the entire ROMCAN cohort of 688 CRC cases and 4567 controls. In addition to the four MMR genes, we focused the analysis on mutations in two other CRC‐associated genes, *APC* and *MUTYH*.[10](#jcmm13881-bib-0010){ref-type="ref"}

2. MATERIALS AND METHODS {#jcmm13881-sec-0002}
========================

2.1. Selection of CRC cases for WGS {#jcmm13881-sec-0003}
-----------------------------------

We selected 61 CRC cases from the ROMCAN and ProMark projects sample collection, a hospital‐based sample set of 4567 cancer cases and controls recruited from five major hospitals in Bucharest between 2008 and 2017. The 61 CRC cases were selected using the following criteria: age at diagnosis lower than 40 years or family history of CRC, endometrial or gastrointestinal tumours. Two of the selected cases are of Roma origin. Both ProMark and ROMCAN are large‐scale genetic epidemiological studies investigating the profile of respectively PrCa and BRC, CRC, LuCa and PrCa in the Romanian population.

All subjects gave written informed consent prior to enrolment and accepted the use of personal and clinical data and biological samples for genetic research. The Bioethical Committee of the Medical School "Carol Davila" approved the study protocols. Trained interviewers performed face‐to‐face interviews, using standardized questionnaires, to collect personal data (ethnicity, marital status, education, height, and weight), lifestyle data (occupation, smoking history, coffee and tea consumption), and medical history (personal and familial). A description of relevant epidemiological and clinical information can be found in Table [1](#jcmm13881-tbl-0001){ref-type="table"}.

###### 

Patient and tumour characteristics of the 61 CRC cases selected for whole‐genome sequencing

                     N    \%
  ------------------ ---- ------
  Male               36   59.0
  Female             25   41.0
  TNM stage               
  T0                 3    4.9
  Tis                3    4.9
  T1                 3    4.9
  T2                 3    4.9
  T3                 34   55.7
  T4                 4    6.6
  T---NA             11   18.0
  N0                 26   42.6
  N1                 15   24.6
  N2                 9    14.8
  NA---N             11   18.0
  M0                 45   73.8
  M1                 5    8.2
  M---NA             11   18.0
  SNOMED code             
  M8480/3            2    3.3
  M8140/3            59   96.7
  ICD10 code              
  C18.0              3    4.9
  C18.2              5    8.2
  C18.3              2    3.3
  C18.4              5    8.2
  C18.5              2    3.3
  C18.6              6    9.8
  C18.7              13   21.3
  C18.8              1    1.6
  C19.9              8    13.1
  C20.9              16   26.2
  Age at diagnosis        
  30‐39 years        9    14.8
  40‐49 years        16   26.2
  50‐59 years        14   23.0
  60‐69 years        15   24.6
  70‐79 years        7    11.5
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2.2. Whole‐genome sequencing and variant calling {#jcmm13881-sec-0004}
------------------------------------------------

DNA isolated from buccal samples from the 61 individuals was subjected to WGS to a targeted average depth of 30x. The samples were prepared following the TruSeq Nano sample preparation method and sequenced on Illumina HiSeq X machines. Sequencing reads were aligned to build 38 of the human reference sequence (GRCh38) using the Burrows‐Wheeler Aligner (BWA).[11](#jcmm13881-bib-0011){ref-type="ref"} Alignments were merged into a single BAM file and marked for duplicates using Picard.[12](#jcmm13881-bib-0012){ref-type="ref"} Only nonduplicate reads were used for the downstream analyses. Variants were called using version 3.8‐0 of the Genome Analysis Toolkit (GATK),[13](#jcmm13881-bib-0013){ref-type="ref"} using a multisample configuration.

2.3. Variant annotation and filtering {#jcmm13881-sec-0005}
-------------------------------------

Variants were annotated using release 8.0 of the Variant Effect Predictor (VEP‐Ensembl).[14](#jcmm13881-bib-0014){ref-type="ref"} To filter out variants over a certain frequency threshold, we used a reference set of 38 000 Icelandic individuals whole‐genome sequenced at deCODE genetics, an extension of a previously described set of 15 220 WGS Icelanders.[15](#jcmm13881-bib-0015){ref-type="ref"} None of the variants described here had any carriers in the Icelandic dataset. Additional frequency filtering was performed using alleles from publicly available datasets of the Exome Aggregation Consortium.[16](#jcmm13881-bib-0016){ref-type="ref"}

2.4. Genetic analysis {#jcmm13881-sec-0006}
---------------------

Only rare (below 1% allelic frequency) coding and splice region variants were considered, including variants with predicted high (stop, frameshift, and splice essential) and moderate (missense, in‐frame, and splice region) impact on protein function. We focused on single‐nucleotide polymorphisms and small indels (\< 20 base pairs). We analysed pathogenic and expected pathogenic mutations in six genes, defined by the American College of Medical Genetics to be high‐risk genes in CRC: *MLH1*,*MSH2*,*MSH6*,*PMS2*,*APC*, and *MUTYH*.[17](#jcmm13881-bib-0017){ref-type="ref"}

2.5. Frequency assessment in the Romanian population {#jcmm13881-sec-0007}
----------------------------------------------------

All 11 coding variants found in the study were genotyped in the entire ROMCAN sample collection of 688 CRC cases, 254 BRC cases, 1457 PrCa cases, 1317 LuCa cases, and 1409 cancer‐free controls. The variants were genotyped using one of two assays: Centaurus[12](#jcmm13881-bib-0012){ref-type="ref"} or KASP.[13](#jcmm13881-bib-0013){ref-type="ref"} Sanger sequencing was used for one variant that failed in both assays. The primer sequences for the assays are listed in Table [S1](#jcmm13881-sup-0001){ref-type="supplementary-material"}.

2.6. Immunohistochemistry {#jcmm13881-sec-0008}
-------------------------

Paraffin blocks with tumour samples from all 11 carriers of variants in the LS genes were collected and sections from them stained for *MLH1*,*MSH6*,*PMS2* to assess if the protein was present. Immunohistochemistry was performed on 3 μm sections. Following deparaffinization in xylene, samples were rehydrated in ethanol and subjected to heat‐induced epitope retrieval (Tris/EDTA buffer, pH 9) in a 98.2°C water bath. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (DAKO). After incubation with the respective primary antibodies for 30 minutes at 20°C, EnVision FLEX Kit (DAKO ref:K8000) was used for detection.

Antibodies used were: Anti‐Human MutL Protein Homolog 1, Clone ES05, (DAKO ref:IR079), Anti‐Human Postmeiotic Segregation, Clone EP51 (DAKO ref:IR087, Anti‐Human MutS Protein Homolog 6, Clone EP49 (DAKO ref:IR086).[18](#jcmm13881-bib-0018){ref-type="ref"}

3. RESULTS {#jcmm13881-sec-0009}
==========

Sequencing of the 61 CRC patients revealed 11 rare coding variants in CRC genes: six variants in *MLH1*, one variant in *MSH6*, one variant in *PMS2*, and three variants in *APC*. We examined literature and clinical trial submission data collected by ClinVar[19](#jcmm13881-bib-0019){ref-type="ref"} with respect to pathogenicity, six out of the 11 variants have been previously reported by ClinVar. All six previously reported variants have a frequency lower than 1% in the ExAC database.[16](#jcmm13881-bib-0016){ref-type="ref"}

For each of the 11 variants, we assessed whether the variants had a high or moderate impact on protein function, based on the location of the mutation within its gene and its predicted molecular consequences (Table [2](#jcmm13881-tbl-0002){ref-type="table"}); frameshift, splice donor or acceptor and stop‐codon gain variants are predicted to have a high impact while in‐frame, missense and splice region variants are predicted to have a moderate impact. To assess the frequencies of the variants in the Romanian population, we genotyped all 11 variants in the ROMCAN cohort: 688 colorectal cases and 4567 cases with cancers other than CRC and controls (254 BRC cases, 1457 PrCa cases, 1317 LuCa cases, and 1409 cancer‐free controls) (Table [3](#jcmm13881-tbl-0003){ref-type="table"}). To test for loss of protein product, we stained MLH1, MSH6, and PMS2 in tumour tissue from paraffin blocks, collected from the carriers of the coding variants.

###### 

Description of the 11 variants in CRC‐associated genes observed in the Romanian population

  Nucleotide change               Ref      Alt   Exon     Position         Predicted protein effect         Consequence       ClinVar   InSIGHT   ACMG       Impact     Gene   IHC   APRP   Carriers in controls/carriers in CRC cases   Comment
  ------------------------------- -------- ----- -------- ---------------- -------------------------------- ----------------- --------- --------- ---------- ---------- ------ ----- ------ -------------------------------------------- --------------------------
  NM_000179.2:c.3202C\>T          C        T     5/10     chr2:47803449    NP_000170.1:p.Arg1068Ter         Stop‐gained       P         P         Tier II    High       MSH6   −     P      0/1                                          --
  NM_000249.3:c.251_255delAACTG   AAACTG   A     3/19     chr3:37000997    NP_000240.1:p.Lys84ThrfsTer4     Frameshift        NA        NA        Tier II    High       MLH1   −     P      0/1                                          Novel
  NM_000249.3:c.1148T\>C          T        C     12/19    chr3:37025746    NP_000240.1:p.Met383Thr          Missense          LP        LP        Tier III   Moderate   MLH1   \+    VUS    0/2                                          --
  NM_000249.3:c.1559‐1G\>C        G        C     intron   chr3:37040185    .                                Splice acceptor   VUS       VUS       Tier II    High       MLH1   −     P      0/1                                          Suggest to classify as P
  NM_000249.3:c.1755dupT          C        CT    16/19    chr3:37047540    NP_000240.1:p.Ala586CysfsTer7    Frameshift        NA        NA        Tier II    High       MLH1   −     P      0/1                                          Novel
  NM_000249.3:c.2041G\>A          G        A     18/19    chr3:37048955    NP_000240.1:p.Ala681Thr          Missense          P         P         Tier II    Moderate   MLH1   −     P      0/1                                          
  NM_000249.3:c.2104‐6T\>C        T        C     Intron   chr3:37050480    .                                Splice region     NA        NA        Tier III   Moderate   MLH1   \+    NP     2/1                                          Novel
  NM_000038.5:c.2780C\>G          C        G     16/16    chr5:112838374   NP_000029.2:p.Ala927Gly          Missense          VUS       NA        Tier III   Moderate   APC    NA    VUS    0/1                                          --
  NM_000038.5:c.3682C\>T          C        T     16/16    chr5:112839276   NP_000029.2:p.Gln1228Ter         Stop‐gained       P         NA        Tier II    High       APC    NA    VUS    0/1                                          --
  NM_000038.5:c.5116T\>A          T        A     16/16    chr5:112840710   NP_000029.2:p.Ser1706Thr         Missense          NA        NA        Tier IV    Moderate   APC    NA    VUS    0/1                                          Novel
  NM_000535.5:c.630dupA           G        GT    6/15     chr7:5999182     NP_000526.1:p.Arg211ThrfsTer38   Frameshift        NA        NA        Tier II    High       PMS2   −     P      0/1                                          Novel

Ref, reference allele; Alt, alternative allele; exon, location of mutation/total number of exons; position, position of the variant in build38; ClinVar---ClinVar classification: P for pathogenic, VUS for variant of uncertain significance, LP for likely pathogenic, NP for not pathogenic and NA for not listed in ClinVar; InSIGHT---InSIGHT classification: P for pathogenic, VUS for variant of uncertain significance, LP for likely pathogenic, NP for not pathogenic and NA for not listed in InSIGHT; ACMG---classification based on the recommendations of the American College of Medical Genetics and Genomics, IHC---results of protein staining of the individuals tumour − means that the protein was not detected, + means that the protein was detected, APRP---Assessment of pathogenicity in the Romanian population represents our own assessment based on the ClinVar, InSIGHT, IHC results and predicted protein effect and is classified as follows: P for pathogenic, NP for not pathogenic, VUS for variant of uncertain significance; comment---this indicates the status of the variant compared to ClinVar and InSIGHT reports.
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###### 

Frequencies of the 11 variants in CRC‐associate genes observed in the Romanian population

  Position in build 38   Predicted protein effect         Reference allele/alternative allele   N carriers in controls genotyped   N controls genotyped   N carriers in lung cancer cases genotyped   N lung cancer cases genotyped   N carriers in breast cancer cases genotyped   N breast cancer cases genotyped   N carriers in prostate cancer cases genotyped   N prostate cancer cases genotyped   N carriers in colorectal cancer cases genotyped   N colorectal cancer cases genotyped   N alleles in EXAC/total alleles in EXAC[a](#jcmm13881-note-0003){ref-type="fn"}
  ---------------------- -------------------------------- ------------------------------------- ---------------------------------- ---------------------- ------------------------------------------- ------------------------------- --------------------------------------------- --------------------------------- ----------------------------------------------- ----------------------------------- ------------------------------------------------- ------------------------------------- ---------------------------------------------------------------------------------
  chr2:47803449          NP_000170.1:p.Arg1068Ter         C/T                                   0                                  1388                   0                                           1148                            0                                             248                               0                                               1446                                1                                                 655                                   18/121286
  chr3:37000997          NP_000240.1:p.Lys84ThrfsTer4     AAACTG/A                              0                                  1392                   0                                           1143                            0                                             239                               0                                               1436                                1                                                 634                                   NA
  chr3:37025746          NP_000240.1:p.Met383Thr          T/C                                   0                                  1357                   1                                           1151                            0                                             242                               0                                               1439                                1                                                 616                                   NA
  chr3:37040185          .                                G/C                                   0                                  1396                   0                                           1151                            0                                             246                               0                                               1447                                2                                                 654                                   NA
  chr3:37047540          NP_000240.1:p.Ala586CysfsTer7    C/CT                                  0                                  1395                   0                                           1140                            0                                             239                               0                                               1440                                1                                                 645                                   NA
  chr3:37048955          NP_000240.1:p.Ala681Thr          G/A                                   0                                  1396                   0                                           1149                            0                                             243                               0                                               1445                                1                                                 658                                   NA
  chr3:37050480          .                                T/C                                   2                                  1385                   0                                           1138                            0                                             241                               0                                               1434                                1                                                 634                                   NA
  chr5:112838374         NP_000029.2:p.Ala927Gly          C/G                                   0                                  1437                   0                                           1148                            0                                             243                               0                                               1422                                1                                                 654                                   4/121082
  chr5:112839276         NP_000029.2:p.Gln1228Ter         C/T                                   0                                  1385                   0                                           1147                            0                                             243                               0                                               1443                                1                                                 642                                   NA
  chr5:112840710         NP_000029.2:p.Ser1706Thr         T/A                                   0                                  1231                   1                                           1082                            0                                             244                               0                                               1269                                1                                                 608                                   NA
  chr7:5999182           NP_000526.1:p.Arg211ThrfsTer38   G/GT                                  0                                  1373                   0                                           1104                            0                                             237                               0                                               1434                                1                                                 640                                   1/121410

To our knowledge, none of the individuals included in the EXAC cohorts are reported to be cancer patients.

John Wiley & Sons, Ltd

We assessed the pathogenicity of these variants in the Romanian population based on IHC results, predicted protein effect and annotation in ClinVar and InSIGHT databases (Table [2](#jcmm13881-tbl-0002){ref-type="table"}, APRP, assessment of pathogenicity in the Romanian population).

We divide our results into two categories; novel variants and previously documented variants. We summarized all reports regarding the pathogenicity of the previously reported variants in Table [S2](#jcmm13881-sup-0002){ref-type="supplementary-material"}, using the output from the ClinVar database. An overview of personal and familial history of cancer for the 11 carriers is listed in Table [4](#jcmm13881-tbl-0004){ref-type="table"}.

###### 

Description of clinical information for the 11 CRC patients with mutations in CRC‐associated genes

  Patient   Variant                   Sex      Age at diagnostic   ICD‐10 code   SNOMED code   Cancer Grade   TNM---T   TNM---N   TNM---M   Relative 1    Age at diagnostic relative 1   Cancer in relative 1   Relative 2   Age at diagnostic relative 2   Cancer in relative 2
  --------- ------------------------- -------- ------------------- ------------- ------------- -------------- --------- --------- --------- ------------- ------------------------------ ---------------------- ------------ ------------------------------ ----------------------
  1         MSH6:p.Arg1068Ter         Male     44                  C18.3         M8140/3       2              T3        N2        M1        Grandfather   54                             CRC                    Uncle        40                             BrC
  2         MLH1:p.Lys84ThrfsTer4     Female   45                  C18.4         M8140/3       2              T3        N1        M0        Sister        42                             CRC                    --           --                             --
  3         MLH1:p.Met383Thr          Female   60                  C18.7         M8140/3       2              T3        N1        M0        Father        59                             BC                     Brother      63                             CRC
  4         MLH1:c.1559‐1G\>C         Female   41                  C18.6         M8140/3       2              T3        N1        M0        Father        49                             CRC                    Brother      42                             CRC
  5         MLH1:c.1559‐1G\>C         Male     43                  C18.2         M8140/3       2              T3        N0        M0        Sister        NA                             CRC                    --           --                             --
  6         MLH1:p.Ala586CysfsTer7    Male     65                  C18.6         M8480/3       2              T3        N1        M0        Brother       37                             CRC                    --           --                             --
  7         MLH1:p.Ala681Thr          Male     47                  C18.6         M8140/3       2              T3        N0        M0        Father        65                             CRC                    --           --                             --
  8         MLH1:c.2104‐6T\>C         Female   50                  C18.7         M8140/3       2              T3        N0        M0        Brother       55                             CRC                    --           --                             --
  9         APC:p.Ser1706Thr          Female   66                  C18.0         M8140/3       2              T3        N0        M0        Father        64                             CRC                    Mother       79                             CRC
  9         APC:p.Ala927Gly           Female   66                  C18.0         M8140/3       2              T3        N0        M0        Father        64                             CRC                    Mother       79                             CRC
  10        APC:p.Gln1228Ter          Male     58                  C18.8         M8140/3       1              Tis       N0        M0        Father        52                             CRC                    --           --                             --
  11        PMS2:p.Arg211ThrfsTer38   Male     44                  C18.7         M8140/3       1              T4        N0        M0        Father        64                             GC                     Brother      36                             GC

Patient---number used in the paper for this individual, relative 1---the first relative with a neoplasic pathology reported by the patient, relative 2---the second relative with a neoplasic pathology reported by the patient.

CRC, colorectal cancer; BC, bone cancer; GC, gastric cancer; BrC, breast cancer.
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3.1. Novel variants {#jcmm13881-sec-0010}
-------------------

### 3.1.1. *MLH1* {#jcmm13881-sec-0011}

*MLH1*: c.251_255delAACTG is a frameshift variant with predicted amino acid change Lys84ThrfsTer4, and consequently assessed as a high impact variant. IHC staining of the tumour of the carrier of this mutation revealed a loss of *MLH1* protein, indicating pathogenicity. We classify this variant as a pathogenic for LS based on the impact of the frameshift mutation and IHC results, classifying this variant as a tier II, level D based on the recommendations of the American College of Medical Genetics and Genomics (ACMG).

*MLH1*:c.1755dupT is a frameshift variant with predicted amino acid change Ala586CysfsTer7, and consequently annotated as a high impact variant. IHC staining of the patient\'s tumour revealed a loss of *MLH1* protein. Based on the impact of the frameshift mutation and IHC result, we classify this variant as a pathogenic for LS, as a tier II, level D based on the recommendations of the ACMG.

*MLH1*:c.2104‐6T\>C is a splice region variant, and consequently annotated as having moderate impact. IHC staining of the patient\'s tumour did not reveal a loss of *MLH1* protein expression. Our results do not support that his variant should be classified as pathogenic. We classify this variant as a tier III based on the recommendations of the ACMG.

### 3.1.2. *PMS2* {#jcmm13881-sec-0012}

The frameshift variant *PMS2*:c.630dupA results in the predicted protein change Arg211ThrfsTer38, and consequently annotated as having high impact. IHC staining showed a loss of *PMS2* protein expression in the carrier of this variant. The patient was diagnosed at age 44 and had extensive family history of gastrointestinal tract cancers. Based on the impact of the frameshift mutation, and IHC, we classify this variant as pathogenic for LS, we classify it as tier II, level D based on the recommendations of the ACMG.

### 3.1.3. *APC* {#jcmm13881-sec-0013}

The missense variant *APC*:c.5116T\>A results in a protein change of Ser1706Thr, and is consequently annotated as having moderate impact. It has not been previously reported either by ClinVar or other studies. According the clinical significance guidelines for classification of sequence variants, we consider this variant to be likely benign, we classify it as tier IV, based on the recommendations of the ACMG. The carrier of this mutation also had a previously reported *APC* variant of uncertain significance (VUS), *APC*:c.2780C\>G (Ala927Gly) described below.

3.2. Previously documented variants {#jcmm13881-sec-0014}
-----------------------------------

### 3.2.1. *MSH6* {#jcmm13881-sec-0015}

*MSH6*:c.3202C\>T (RS63749843), is a stop‐gained variant, assessed as a high impact variant with a protein change of Arg1068Ter. This variant was previously reported as pathogenic in ClinVar by 10 different submitters involved in clinical testing and research. Tumour sample from the carrier of this variant had loss of *MSH6* protein expression, further supporting its pathogenicity. We classify this variant as a tier II, level D based on the recommendations of the ACMG.

### 3.2.2. *MLH1* {#jcmm13881-sec-0016}

*MLH1*:c.1148T\>C (RS141344760) is a missense variant, and consequently of moderate predicted impact, resulting in a protein change of Met383Thr. IHC staining of the carrier\'s tumour showed positive protein expression for *MLH1*. The variant was previously reported as being of uncertain significance in ClinVar by five different submitters from clinical testing and research and our results do not support pathogenicity. We classify this variant as a tier III based on the recommendations of the ACMG.

*MLH1*:c.1559‐1G\>C is a splice acceptor variant, annotated as high impact. This was the only candidate mutation found in two CRC cases. The tumour samples from both carriers had lost MLH1 protein and both had documented family history or CRC. The variant has been reported previously by two different submitters as likely pathogenic for LS and our results indicate that the variant is pathogenic. We classify this variant as a tier II, level D based on the recommendations of the ACMG.

*MLH1*:c.2041G\>A (rs63750217) is a missense with a predicted protein change of Ala681Thr, and consequently of moderate impact. The tumour of the carrier had loss of *MLH1* protein staining. This variant was previously reported as pathogenic in ClinVar by nine different submitters from clinical testing and research. In addition, OMIM has classified the variant as pathogenic for LS II. We classify this variant as a tier II, level D based on the recommendations of the ACMG.

### 3.2.3. *APC* {#jcmm13881-sec-0017}

*APC*:c.2780C\>G (rs587781500) results in the amino acid change Ala927Gly and consequently of moderate impact. It was previously reported as a VUS in ClinVar by four different submitters from clinical testing. We classify this variant as tier III based on the recommendations of the ACMG. As mentioned above, the carrier also had another likely benign variant in *APC*,*APC*:c.5116T\>A (Ser1706Thr).

*APC*:c.3682C\>T is a stop‐gained variant resulting in the protein change Gln1228Ter, and consequently of high impact. It was reported in ClinVar by a single submitter as pathogenic for familial multiple polyposis syndrome and was found in a recent study investigating somatic *APC* mutations and loss of heterozygosity status for 630 patients with sporadic CRC.[14](#jcmm13881-bib-0014){ref-type="ref"} We classify this variant as a tier II, level D based on the recommendations of the ACMG.

4. DISCUSSIONS {#jcmm13881-sec-0018}
==============

This study is the first assessment of rare variants underlying LS in CRC patients in Romanians. We identify new variants specific to the Romanian population and show that some variants previously reported to be pathogenic in other populations also occur in Romania.

We identified three novel pathogenic variants, two novel variants that are unlikely to be pathogenic. Also, we confirmed three previously published pathogenic variants and suggest to reclassify a variant previously classified as VUS as pathogenic. Due to study limitations, we were not able to classify the three *APC* variants identified in the Romanian population. We note that out of the two rare missense variants in APC identified in the same individual, we classify one as a likely benign variant based on ACMG\'s guidelines for classification of sequence variants.[20](#jcmm13881-bib-0020){ref-type="ref"} The other variant, p.Ala927Gly, has been reported previously as a VUS, but we note that it is located within a critical domain, intolerant to mutations. Our present study is the first one, to our knowledge, to examine rare sequence variants associated with CRC in the Romanian population.

In total, we identified six pathogenic variants, one nonpathogenic variant and four variants of uncertain significance in the Romanian population. In order to determine the prevalence of these variants in Romania, we assessed the frequencies of the 11 variants in the full ROMCAN cohort. As described in Table [3](#jcmm13881-tbl-0003){ref-type="table"}, none of the mutations were found in more than 1 CRC patients except for *MLH1*:c.1559‐1G\>C. Our results do not suggest any strong association between the 11 variants identified here and BRC, LuCa or PrCa.

Identification of LS variants in the Romanian population is important in order to reduce the incidence and mortality of this multicancer disorder. Our present study is the largest effort, to our knowledge, to examine the genetic profile of this pathology in Eastern Europe. Due to study limitations, we were not able to extrapolate any other clinical observations, and we emphasize the need for future follow‐up studies in the Romanian population. This study is the first step towards improving our understanding of the genetic particularities of this pathology in Romania and provides new insights for the scientific community studying the genetic epidemiology of LS.
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